Genetic Engineering of T Cells for Immune Tolerance

David W. Scott

doi:10.1016/j.omtm.2019.11.022

Genetic Engineering of T Cells for Immune Tolerance

David W. Scott^*

^*Corresponding author for this work

Medicine

Research output: Contribution to journal › Review article › peer-review

6 Scopus citations

Abstract

Regulatory T cells (Tregs) play a role in the induction and maintenance of tolerance, as well as in modulating aberrant immune responses. While expanded Tregs have been used in clinical trials, they are polyclonal and the frequency of specific Tregs is very low. To overcome this issue, we have endeavored to “specify” Tregs by engineering them to express receptors that can recognize a given antigen and applied this protocol in autoimmunity, hemophilia and allergy. Thus, we have used retroviral transduction of a specific T cell receptor, single-chain variable fragments (Fvs), or antigen domains in Tregs to achieve this goal. This review summarizes our steps to achieve the ultimate goal of modulating human diseases.

Original language	English
Pages (from-to)	103-107
Number of pages	5
Journal	Molecular Therapy - Methods and Clinical Development
Volume	16
DOIs	https://doi.org/10.1016/j.omtm.2019.11.022
State	Published - 13 Mar 2020

Access to Document

10.1016/j.omtm.2019.11.022

Cite this

@article{cd0e805e807b4e94a25d27e36c8ff3b4,

title = "Genetic Engineering of T Cells for Immune Tolerance",

abstract = "Regulatory T cells (Tregs) play a role in the induction and maintenance of tolerance, as well as in modulating aberrant immune responses. While expanded Tregs have been used in clinical trials, they are polyclonal and the frequency of specific Tregs is very low. To overcome this issue, we have endeavored to “specify” Tregs by engineering them to express receptors that can recognize a given antigen and applied this protocol in autoimmunity, hemophilia and allergy. Thus, we have used retroviral transduction of a specific T cell receptor, single-chain variable fragments (Fvs), or antigen domains in Tregs to achieve this goal. This review summarizes our steps to achieve the ultimate goal of modulating human diseases.",

author = "Scott, \{David W.\}",

note = "Publisher Copyright: {\textcopyright} 2019",

year = "2020",

month = mar,

day = "13",

doi = "10.1016/j.omtm.2019.11.022",

language = "English",

volume = "16",

pages = "103--107",

journal = "Molecular Therapy - Methods and Clinical Development",

issn = "2329-0501",

publisher = "Cell Press",

}

TY - JOUR

T1 - Genetic Engineering of T Cells for Immune Tolerance

AU - Scott, David W.

PY - 2020/3/13

Y1 - 2020/3/13

N2 - Regulatory T cells (Tregs) play a role in the induction and maintenance of tolerance, as well as in modulating aberrant immune responses. While expanded Tregs have been used in clinical trials, they are polyclonal and the frequency of specific Tregs is very low. To overcome this issue, we have endeavored to “specify” Tregs by engineering them to express receptors that can recognize a given antigen and applied this protocol in autoimmunity, hemophilia and allergy. Thus, we have used retroviral transduction of a specific T cell receptor, single-chain variable fragments (Fvs), or antigen domains in Tregs to achieve this goal. This review summarizes our steps to achieve the ultimate goal of modulating human diseases.

AB - Regulatory T cells (Tregs) play a role in the induction and maintenance of tolerance, as well as in modulating aberrant immune responses. While expanded Tregs have been used in clinical trials, they are polyclonal and the frequency of specific Tregs is very low. To overcome this issue, we have endeavored to “specify” Tregs by engineering them to express receptors that can recognize a given antigen and applied this protocol in autoimmunity, hemophilia and allergy. Thus, we have used retroviral transduction of a specific T cell receptor, single-chain variable fragments (Fvs), or antigen domains in Tregs to achieve this goal. This review summarizes our steps to achieve the ultimate goal of modulating human diseases.

UR - https://www.scopus.com/pages/publications/85077460120

U2 - 10.1016/j.omtm.2019.11.022

DO - 10.1016/j.omtm.2019.11.022

M3 - Review article

AN - SCOPUS:85077460120

SN - 2329-0501

VL - 16

SP - 103

EP - 107

JO - Molecular Therapy - Methods and Clinical Development

JF - Molecular Therapy - Methods and Clinical Development

ER -

Genetic Engineering of T Cells for Immune Tolerance

Abstract

Access to Document

Fingerprint

Cite this